These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. A unique binding mode of the eukaryotic translation initiation factor 4E for guiding the design of novel peptide inhibitors. Di Marino D; D'Annessa I; Tancredi H; Bagni C; Gallicchio E Protein Sci; 2015 Sep; 24(9):1370-82. PubMed ID: 26013047 [TBL] [Abstract][Full Text] [Related]
43. Synaptic vesicle dynamic changes in a model of fragile X. Broek JAC; Lin Z; de Gruiter HM; van 't Spijker H; Haasdijk ED; Cox D; Ozcan S; van Cappellen GWA; Houtsmuller AB; Willemsen R; de Zeeuw CI; Bahn S Mol Autism; 2016; 7():17. PubMed ID: 26933487 [TBL] [Abstract][Full Text] [Related]
44. Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome. Berry-Kravis EM; Lindemann L; Jønch AE; Apostol G; Bear MF; Carpenter RL; Crawley JN; Curie A; Des Portes V; Hossain F; Gasparini F; Gomez-Mancilla B; Hessl D; Loth E; Scharf SH; Wang PP; Von Raison F; Hagerman R; Spooren W; Jacquemont S Nat Rev Drug Discov; 2018 Apr; 17(4):280-299. PubMed ID: 29217836 [TBL] [Abstract][Full Text] [Related]
45. NNZ-2566, a novel analog of (1-3) IGF-1, as a potential therapeutic agent for fragile X syndrome. Deacon RM; Glass L; Snape M; Hurley MJ; Altimiras FJ; Biekofsky RR; Cogram P Neuromolecular Med; 2015 Mar; 17(1):71-82. PubMed ID: 25613838 [TBL] [Abstract][Full Text] [Related]
47. The fragile X syndrome: exploring its molecular basis and seeking a treatment. Bardoni B; Davidovic L; Bensaid M; Khandjian EW Expert Rev Mol Med; 2006 Apr; 8(8):1-16. PubMed ID: 16626504 [TBL] [Abstract][Full Text] [Related]
48. Brief report: acamprosate in fragile X syndrome. Erickson CA; Mullett JE; McDougle CJ J Autism Dev Disord; 2010 Nov; 40(11):1412-6. PubMed ID: 20213249 [TBL] [Abstract][Full Text] [Related]
49. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Jacquemont S; Curie A; des Portes V; Torrioli MG; Berry-Kravis E; Hagerman RJ; Ramos FJ; Cornish K; He Y; Paulding C; Neri G; Chen F; Hadjikhani N; Martinet D; Meyer J; Beckmann JS; Delange K; Brun A; Bussy G; Gasparini F; Hilse T; Floesser A; Branson J; Bilbe G; Johns D; Gomez-Mancilla B Sci Transl Med; 2011 Jan; 3(64):64ra1. PubMed ID: 21209411 [TBL] [Abstract][Full Text] [Related]
50. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. Berry-Kravis E; Sumis A; Hervey C; Nelson M; Porges SW; Weng N; Weiler IJ; Greenough WT J Dev Behav Pediatr; 2008 Aug; 29(4):293-302. PubMed ID: 18698192 [TBL] [Abstract][Full Text] [Related]
51. Status epilepticus in fragile X syndrome. Gauthey M; Poloni CB; Ramelli GP; Roulet-Perez E; Korff CM Epilepsia; 2010 Dec; 51(12):2470-3. PubMed ID: 21204809 [TBL] [Abstract][Full Text] [Related]
52. Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome. Nosyreva ED; Huber KM J Neurophysiol; 2006 May; 95(5):3291-5. PubMed ID: 16452252 [TBL] [Abstract][Full Text] [Related]
53. Bryostatin-1 restores hippocampal synapses and spatial learning and memory in adult fragile x mice. Sun MK; Hongpaisan J; Lim CS; Alkon DL J Pharmacol Exp Ther; 2014 Jun; 349(3):393-401. PubMed ID: 24659806 [TBL] [Abstract][Full Text] [Related]
54. Medication use by adolescents and adults with fragile X syndrome. Laxman DJ; Greenberg JS; DaWalt LS; Hong J; Aman MG; Mailick M J Intellect Disabil Res; 2018 Feb; 62(2):94-105. PubMed ID: 29034517 [TBL] [Abstract][Full Text] [Related]
55. Biomimetic photocycloaddition of 3-hydroxyflavones: synthesis and evaluation of rocaglate derivatives as inhibitors of eukaryotic translation. Roche SP; Cencic R; Pelletier J; Porco JA Angew Chem Int Ed Engl; 2010 Sep; 49(37):6533-8. PubMed ID: 20687060 [No Abstract] [Full Text] [Related]
56. Fragile X mental retardation protein: A paradigm for translational control by RNA-binding proteins. Chen E; Joseph S Biochimie; 2015 Jul; 114():147-54. PubMed ID: 25701550 [TBL] [Abstract][Full Text] [Related]
57. A novel fragile X syndrome mutation reveals a conserved role for the carboxy-terminus in FMRP localization and function. Okray Z; de Esch CE; Van Esch H; Devriendt K; Claeys A; Yan J; Verbeeck J; Froyen G; Willemsen R; de Vrij FM; Hassan BA EMBO Mol Med; 2015 Apr; 7(4):423-37. PubMed ID: 25693964 [TBL] [Abstract][Full Text] [Related]
58. Autism and the synapse: emerging mechanisms and mechanism-based therapies. Ebrahimi-Fakhari D; Sahin M Curr Opin Neurol; 2015 Apr; 28(2):91-102. PubMed ID: 25695134 [TBL] [Abstract][Full Text] [Related]
59. Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes. Wang H; Pati S; Pozzo-Miller L; Doering LC Front Cell Neurosci; 2015; 9():55. PubMed ID: 25767435 [TBL] [Abstract][Full Text] [Related]